DelveInsight’s, “Meningioma Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Meningioma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Meningioma Pipeline Outlook

Key Takeaways from the Meningioma Pipeline Report

• In May 2025, European Organisation for Research and Treatment of Cancer – EORTC conducted a LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine “theranostic” concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
• In May 2025, Baptist Health South Florida announced a phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma.
• DelveInsight’s Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment.
• The leading Meningioma Companies such as NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
• Promising Meningioma Pipeline Therapies such as Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.

Stay ahead with the most recent pipeline outlook for Meningioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Meningioma Treatment Drugs

Meningioma Emerging Drugs Profile

• Gleolan: NX Devolopment Corp

NX development corp.’s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissue destruction.

• Nivolumab: Bristol-Myers Squibb

Bristol-Myers Squibb “breakthrough” drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumor response.

The Meningioma Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Meningioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meningioma Treatment.
• Meningioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Meningioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meningioma market

Explore groundbreaking therapies and clinical trials in the Meningioma Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Meningioma Drugs

Meningioma Companies

NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.

Meningioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Meningioma Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Unveil the future of Meningioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Meningioma Market Drivers and Barriers

Scope of the Meningioma Pipeline Report

• Coverage- Global
• Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
• Meningioma Pipeline Therapies- Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
• Meningioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Meningioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Meningioma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Meningioma Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Meningioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Meningioma – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Meningioma Collaboration Deals
9. Late Stage Products (Phase III)
10. Gleolan: Nx Development Corp.
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Nivolumab: Bristol-Myers Squibb
14. Drug profiles in the detailed report…..
15. Pre-clinical and Discovery Stage Products
16. Drug profiles in the detailed report…..
17. Inactive Products
18. Meningioma Key Companies
19. Meningioma Key Products
20. Meningioma- Unmet Needs
21. Meningioma- Market Drivers and Barriers
22. Meningioma- Future Perspectives and Conclusion
23. Meningioma Analyst Views
24. Meningioma Key Companies
25. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-pipeline-insight